Bagsværd, Denmark, 24 May 2016 - Novo Nordisk today announced that
the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food
and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira
for the treatment of adults with type 2 diabetes. IDegLira is a once-daily,
single injection fixed combination of insulin degludec (Tresiba(®)) and
liraglutide (Victoza(®)) for the treatment of adults with type 2 diabetes.
Based on the data contained in the New Drug Appl
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.